Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib platform study of spartalizumab + LAG525 combinations in advanced triple-negative breast cancer
NL-OMON49712Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- Jun 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of spartalizumab, ieramilimab, taminadenant, capmatinib, lacnotuzumab and 1 more in triple-negative breast cancer (TNBC) (4 arms), sponsored by Novartis. Primary endpoints: Safety and tolerability and Dose-limiting toxicities. Started Jun 2019; status: active, not recruiting.
02
Drugs
spartalizumabieramilimabtaminadenantcapmatiniblacnotuzumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NL-OMON49712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49712.